Baird Rates REGENXBIO (RGNX) buy, $32 Price Target

Baird maintains its buy rating on RGNX with a $32 price target, a 310.26% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 3:01 PM EDT · Updated Jun 22, 2026, 9:06 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Baird rated REGENXBIO Inc. ($RGNX) "buy" with a $32 price target on June 22, 2026.

Since the rating, $RGNX is up 30.4% after 1 week, up 12.5% after 1 month and down 23.7% to date (from the $9.07 close on Jun 22, 2026).

RGNX REGENXBIO Inc.

$6.92 -49.01% year to date

Daily close · Oct 16, 2026

Key Points

Baird reiterated a buy rating on RGNX with a $32 price target on June 22, 2026.
Baird's $32 price target implies 310.26% upside from REGENXBIO Inc.'s ($RGNX) current $7.80 share price.
RGNX shares traded at $7.80 on Monday amid insider buying activity.
BlackRock and State Street adjusted their RGNX positions, while Vanguard opened a new stake.

Get $RGNX trade alerts by text

We text you when insiders, Congress or big funds trade $RGNX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated REGENXBIO Inc. alert may contain errors. Disclosures

On June 22, 2026, Baird analyst Brian Skorney reiterated his buy rating on RGNX, maintaining a price target of $32. This comes as the stock traded at approximately $7.80 on Monday.

Analyst rating track record

Baird vs. the S&P 500

YTD return +6.10% hypothetical

All-time return +11.45% S&P 500 +29.11%

vs. S&P 500 -17.66% behind the index

Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in RGNX

BlackRock, Inc. grew its holdings by 25,997 shares, bringing its total to about 5.78 million shares valued at $48.46 million. State Street Corp significantly increased its position by 444,749 shares to a total of 2.73 million shares, worth around $22.89 million. Meanwhile, JPMorgan Chase & Co reduced its holdings by 69,702 shares, leaving it with 3.48 million shares valued at $27.07 million. Morgan Stanley added 51,369 shares, ending with 2.07 million shares valued at $17.31 million. Vanguard Capital Management LLC opened a new position with approximately 2 million shares valued at $16.82 million.

REGENXBIO Inc. Stock Down 2.9%

Shares of RGNX traded near $7.80 on Monday. While specific market cap and P/E ratio data are not provided, the stock has seen recent activity from both institutional investors and analysts.

12-month forecast

$RGNX price target

REGENXBIO Inc. daily closes and this analyst's $32 target. Not advice.

Insider Buying and Selling at REGENXBIO Inc.

Several insiders made notable buys on May 29, 2026. Daniel Tasse, Kenneth Mills, and David Stump each acquired 46,600 shares. Additionally, Kenneth Mills, Allan Fox, and Alexandra Glucksmann each purchased 9,807 shares. These transactions were not part of planned trading programs.

Analysts Set New Price Targets

On June 22, 2026, Baird maintained its buy rating with a $32 price target. Leerink Partners also maintained a buy rating, setting a target of $18. Earlier in June, HC Wainwright & Co. reiterated its buy rating with a $26 target on June 5. The consensus among analysts is bullish, with a strong buy recommendation and a mean price target reflecting optimism for RGNX's prospects.

Bottom Line

Baird's reaffirmation of its buy rating with a $32 target reflects continued confidence in RGNX. While the stock traded at $7.80 recently, insider buying and institutional adjustments indicate active interest. As with all 13F filings and analyst ratings, these insights are backward-looking and serve as a snapshot of sentiment at the time.